Coss Alan, Tosetto Miriam, Fox Edward J, Sapetto-Rebow Beata, Gorman Sheeona, Kennedy Breandán N, Lloyd Andrew T, Hyland John M, O'Donoghue Diarmuid P, Sheahan Kieran, Leahy Dermot T, Mulcahy Hugh E, O'Sullivan Jacintha N
Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
Cancer Lett. 2009 Apr 18;276(2):228-38. doi: 10.1016/j.canlet.2008.11.018. Epub 2008 Dec 25.
Topoisomerase IIalpha is a nuclear enzyme that regulates the tertiary structure of DNA. The influence of topoisomerase IIalpha gene (TOP2A) or protein alterations on disease progression and treatment response in colorectal cancer (CRC) is unknown. The study investigated the clinical relevance of topoisomerase IIalpha in CRC using in vivo and in vitro models. Differentially expressed genes in early and late-stage CRC were identified by array comparative genomic hybridization (CGH). Cellular location of gene amplifications was determined by fluorescence in situ hybridization (FISH). Topoisomerase IIalpha levels, proliferation index, and HER2 expression were examined in 228 colorectal tumors by immunohistochemistry. Overexpression of topoisomerase IIalpha in vitro was achieved by liposome-based transfection. Cell growth inhibition and apoptosis were quantified using the crystal violet assay and flow cytometry, respectively, in response to drug treatment. Amplification of TOP2A was identified in 3 (7.7%) tumors using array CGH and confirmed using FISH. At the protein level, topoisomerase IIalpha staining was observed in 157 (69%) tumors, and both staining and intensity levels were associated with an aggressive tumor phenotype (p values 0.04 and 0.005, respectively). Using logistic regression analysis, topoisomerase IIalpha remained significantly associated with advanced tumor stage when corrected for tumor proliferation (p=0.007) and differentiation (p=0.001). No association was identified between topoisomerase IIalpha and HER2. In vitro, overexpression of topoisomerase IIalpha was associated with resistance to irinotecan (p=0.001) and etoposide chemotherapy (p=0.03), an effect mediated by inhibition of apoptosis. Topoisomerase IIalpha overexpression is significantly associated with alterations in tumor behavior and response to drug treatment in CRC. Our results suggest that gene amplification may represent an important mechanism underlying these changes.
拓扑异构酶IIα是一种调节DNA三级结构的核酶。拓扑异构酶IIα基因(TOP2A)或蛋白质改变对结直肠癌(CRC)疾病进展和治疗反应的影响尚不清楚。本研究使用体内和体外模型研究了拓扑异构酶IIα在CRC中的临床相关性。通过阵列比较基因组杂交(CGH)鉴定早期和晚期CRC中差异表达的基因。通过荧光原位杂交(FISH)确定基因扩增的细胞定位。通过免疫组织化学检测228例结直肠肿瘤中的拓扑异构酶IIα水平、增殖指数和HER2表达。通过基于脂质体的转染在体外实现拓扑异构酶IIα的过表达。分别使用结晶紫测定法和流式细胞术对药物治疗后的细胞生长抑制和凋亡进行定量。使用阵列CGH在3例(7.7%)肿瘤中鉴定出TOP2A扩增,并使用FISH进行确认。在蛋白质水平上,在157例(69%)肿瘤中观察到拓扑异构酶IIα染色,染色和强度水平均与侵袭性肿瘤表型相关(p值分别为0.04和0.005)。使用逻辑回归分析,在校正肿瘤增殖(p=0.007)和分化(p=0.001)后,拓扑异构酶IIα仍与晚期肿瘤分期显著相关。未发现拓扑异构酶IIα与HER2之间存在关联。在体外,拓扑异构酶IIα的过表达与对伊立替康(p=0.001)和依托泊苷化疗(p=0.03)的耐药性相关,这种效应是由凋亡抑制介导的。拓扑异构酶IIα过表达与CRC中肿瘤行为改变和药物治疗反应显著相关。我们的结果表明基因扩增可能是这些变化的重要潜在机制。